media – Page 383 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Bristol Myers Squibb and Tubulis partner in deal worth over $1bn

The agreement is aimed at developing differentiated ADCs for solid tumours Bristol Myers Squibb (BMS) and Tubulis have announced an agreement aimed at developing differentiated antibody-drug conjugates (ADCs) for solid tumours. ADCs are a class of potent cancer therapies combining the selectivity of antibodies with the potent cell-killing properties of chemotherapy or other anti-cancer agents. Unlike chemotherapy, which works by attacking lots of different cells as well as the cancer, ADCs are designed to target and kill tumour cells while sparing healthy ones. Under the terms of the licensing agreement, the German biotech will receive an upfront payment of $22.75m from BMS and will be eligible for future payments of over $1bn plus royalties. In exchange, BMS will gain exclusive rights to Tubulis’ Tubutecan payloads and P5 conjugation platform for the development of a selected number of highly differentiated ADCs to treat solid tumours. ...
- Source: drugdu
- 143
- May 5, 2023
ChatGPT outshines physicians in quality and empathy for online patient queries

By Neha Mathur In a recent study published in JAMA Internal Medicine, researchers evaluated the ability of ChatGPT, an artificial intelligence-based chatbot assistant, to respond to patient questions posted on a publically accessible social media forum. Background Owing to the quick expansion of digital health care, more and more patients have begun to raise queries on social media forums. Answering these questions is not just time-consuming but tedious for healthcare professionals. AI assistants, like ChatGPT, could help address this additional work and help draft quality responses, which later clinicians could review. About the study In the present cross-sectional study, researchers randomly drew 195 exchanges in response to a patient question asked over Reddit’s r/AskDocs, a publically accessible social media forum, in October 2022. Then, a team of licensed healthcare professionals generated a new chatbot session using the original full text of the question to which a physician responded and then evaluated the ...
- Source: drugdu
- 144
- May 5, 2023
Mpox outbreak was wake-up call for smallpox preparation, vaccine maker Bavarian Nordic says

The maker of the mpox vaccine is looking at ways to dramatically scale up its production capacity to prepare for a potential threat from smallpox. Bavarian Nordic CEO Paul Chaplin said the rapid spread of mpox last year was a wake-up call for the company, which is based in Denmark. “If it wasn’t mpox but it was smallpox, we are completely at the wrong scale,” Chaplin told CNBC in an interview. “We’re looking at ways we can dramatically change the way we manufacture to increase our scale,” he said. Mpox is in the same virus family as smallpox. Bavarian Nordic’s Jynneos vaccine is approved by the U.S. Food and Drug Administration to protect against both pathogens. Previously known as monkeypox, the World Health Organization changed the name to mpox last year to reduce stigma. Bavarian Nordic plans to simplify its production process so ...
- Source: drugdu
- 104
- May 5, 2023
African psychedelic plant medicine inspires new drug candidates for treating addiction and depression

Scientists have developed two new drug candidates for potentially treating addiction and depression, modeled on the pharmacology of a traditional African psychedelic plant medicine called ibogaine. At very low doses, these new compounds were able to blunt symptoms of both conditions in mice. The findings, published on May 2 in Cell, took inspiration from ibogaine’s impact on the serotonin transporter (SERT), which is also the target of SSRI antidepressants like fluoxetine (Prozac). A team of scientists from UCSF, Yale and Duke universities virtually screened 200 million molecular structures to find ones that blocked SERT in the same way as ibogaine. “Some people swear by ibogaine for treating addiction, but it isn’t a very good drug. It has bad side effects, and it’s not approved for use in the U.S. Our compounds mimic just one of ibogaine’s many pharmacological effects, and still replicate its most desirable effects on behavior, ...
- Source: drugdu
- 121
- May 5, 2023
Pfizer Acquires COVID-Flu Test Developer Lucira Health for USD 36.4 Million

By LabMedica International staff writers Pfizer Inc. (New York, NY, USA) has acquired Lucira Health, Inc. (Emeryville, CA, USA) for USD 36.4 million in a bankruptcy auction. Lucira filed for bankruptcy in February 2023, just two days before receiving FDA Emergency Use Authorization (EUA) for the first over-the-counter (OTC) at-home diagnostic test capable of differentiating and detecting influenza A and B. The COVID-19 & Flu Home Test is a single-use at-home test kit that delivers results from self-collected nasal swab samples in about 30 minutes. Lucira had previously received the first FDA EUA for an at-home rapid self-test, the Lucira COVID-19 All-in-One Test Kit, in November 2020, and the company announced in April 2021 that it had secured OTC EUA for its Lucira Check It test kit for SARS-CoV-2. The company’s tests use a handheld battery-powered real-time testing instrument with nasal swab samples and loop-mediated isothermal amplification to provide ...
- Source: drugdu
- 118
- May 5, 2023
Study shows link between obesity and adverse postoperative outcomes

In the United States, almost 74% of adults age 20 and older have overweight or obesity, and of that number almost 42% have obesity. Not only are overweight and obesity complex and serious diseases, but clinicians and researchers are continuing to learn how they can impact health outcomes – from heart and musculoskeletal health to risk for disease, including cancer. New research published in the journal SURGERY shows that obesity is also associated with increased risk of complications following surgery, including infection, blood clots, and kidney complications. “We need to continue to recognize that overweight and obesity can have medical impacts that aren’t limited to heart disease and diabetes and liver failure. They can also make recovery from surgery harder, and these data can inform the conversation happening at a broader public health level addressing obesity.” Robert Meguid, MD, MPH, researcher, professor of cardiothoracic surgery in the ...
- Source: drugdu
- 178
- May 5, 2023
Fingerpaint, spying growing vaccine market, buys MYND to expand market access capabilities

Fingerpaint Group has a mind to draw biopharma companies a clearer picture of their market access options—and now it has MYND to help it do so. By acquiring MYND Group, Fingerpaint has continued its takeover spree and added to the capabilities of its recently rebranded market access group. Healthcare marketing agency Fingerpaint moved into market access early in 2020 with the acquisition of 1798, a California-based developer of market access and commercialization support programs. Late last year, Fingerpaint dropped the 1798 name. Rebranded as Fingerpaint Market Access, the unit, which had been involved in 30 launches in the previous three years, pitched itself as an end-to-end consultancy. Now, Fingerpaint has added to its market access capabilities. MYND is a Pennsylvania-based provider of a range of market access services, spanning from market research through to the training of sales teams. The services overlap with Fingerpaint’s existing capabilities. In a statement, Bill McEllen, global president ...
- Source: drugdu
- 118
- May 5, 2023
WHO and global partners launch new effort to address falling childhood vaccination rates Over 25 million children missed at least one vaccination in 2021 alone

WHO The World Health Organization (WHO), along with other global and national health partners, has launched a global effort to boost vaccination among children following declines driven by the COVID-19 pandemic. WHO, UNICEF, Gavi, the Vaccine Alliance, the Bill & Melinda Gates Foundation and others announced ‘The Big Catch-Up’ to reverse the declines and protect populations from vaccine-preventable outbreaks such as measles, polio and yellow fever. Over 25 million children missed at least one vaccination in 2021, and the effort will focus on the 20 countries where 75% of these children live. WHO director-general, Dr Tedros Adhanom Ghebreyesus, said: “Millions of children and adolescents, particularly in lower-income countries, have missed out on life-saving vaccinations, while outbreaks of these deadly diseases have risen. “WHO is supporting dozens of countries to restore immunisation and other essential health services. Catching up is a top priority. ...
- Source: drugdu
- 131
- May 5, 2023
A high proportion of adults in Europe do not have protective antibody concentrations against diphtheria

In a recent study published in the Eurosurveillance Journal, researchers conducted a retrospective analysis of seroprotection against tetanus and diphtheria among residents in Austria following an increase in diphtheria cases since 2022 in Europe. Background Diphtheria is an infection caused by Corynebacterium diphtheriae resulting in the inflammation of mucous membranes in the throat and nose. While an increase in the incidence of diphtheria among migrants in Europe was observed beginning in August 2022, recent studies also found that the concentrations of antibodies against diphtheria in adults in approximately 18 countries in the European Union were negligible. Although no diphtheria outbreaks have been reported among the general population of European Union countries, the low seroprotection increases the risk of disease outbreaks. Estimating the seroprevalence among the population could help determine the risk of a diphtheria outbreak and increase awareness about the importance of vaccines to ensure ...
- Source: drugdu
- 151
- May 3, 2023
Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report says

Johnson & Johnson’s consumer health business is valued at $40 billion ahead of its initial public offering later this year, according to a report by The Wall Street Journal. The soon-to-be spinoff Kenvue aims to raise $3.5 billion or more in the offering, people familiar with the matter told the Journal. The newspaper noted that “the share sale would be by far the biggest of what so far has been a quiet year for IPOs.” Kenvue plans to meet with prospective investors as early as Monday, the sources told the Journal. When asked about the Journal’s report, J&J spokesperson Tesia Williams told CNBC, “Unfortunately, I do not have any information to provide.” J&J previously said it expects to complete the separation from Kenvue by mid- to late 2023. The consumer staples giant has also said it will retain majority ownership of Kenvue, with ...
- Source: drugdu
- 155
- May 3, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.